Disc Medicine (IRON) Receivables - Other (2020 - 2021)
Disc Medicine (IRON) reported Receivables - Other of $6000.0 for Q1 2021, up 857042.86% on a QoQ basis from $0.7 in Q4 2020.
Disc Medicine (IRON) has 2 years of Receivables - Other data on file, last reported at $6000.0 in Q1 2021.
- Quarterly Receivables - Other changed N/A year-over-year to $6000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $6000.0 (changed N/A YoY) and the FY2020 annual result came in at $0.7, changed N/A from the prior year.
- Receivables - Other improved to $6000.0 in Q1 2021 per IRON's latest filing, from $0.7 in the prior quarter.
- Across five years, Receivables - Other topped out at $6000.0 in Q1 2021 and bottomed at $0.7 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 6,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Dec 31, 2020 | 0.70 |
| Dec 31, 2020 | 0.70 |